Clinical outcome of patients with diabetes mellitus infected by SARS-COV-2
DOI:
https://doi.org/10.26694/repis.v8i1.4535Palavras-chave:
COVID-19, SARS-CoV-2, Diabetes Mellitus, Diabetes ComplicationsResumo
Introduction: Diabetes, a chronic metabolic disease with high prevalence in Brazil, is a risk factor for severe SARS COV-2 infection. The relationship between previous glycemic control and the prognosis of patients hospitalized with COVID-19 is not fully understood. Objective: analyze the clinical outcome of patients with diabetes mellitus infected by SARS-COV-2. Outlining: A retrospective analysis of medical records was carried out using the Trakcare electronic system of all diabetic patients hospitalized with a confirmatory diagnosis of pneumonia due to COVID-19 in the medical clinic ward of HRAN, from June to August 2021, who, upon admission, performed the glycated hemoglobin test and analyzed it using the SPSS software (20.0). Results: A sample of 52 patients was obtained during the study period. Most patients are female, with a mean age of approximately 58 years. The comorbidity most associated with the participants was systemic arterial hypertension, with most diabetics presenting good prior glycemic control, represented by HbA1c ≤ 7%. The lethality found was 7.7%. Implications: The study shows a high lethality of diabetic patients infected by COVID 19, but no statistical significance was found for HbA1c levels with the increase in length of stay, use of non-rebreathing mask, need for invasive mechanical ventilation or lethality
Referências
Moura MEB, Sousa Neto AR de, Chissamba RE, Carvalho ARB de, Peres NVG, Oliveira TA de, Valle ARM da C, Freitas DRJ de. Global trends from original research on COVID-19 and coinfection. Rev. Pre Infec e Saúde [Internet]. 2023 [cited 2023 Jun 28]; 8(1). Available from: https://doi.org/10.26694/repis.v8i1.4208
Coronavirus Disease 2019. Centers for Disease Control and Prevention; 2020. [cited 2021 Jun 28]. Available from: // https://www.cdc.gov/media/releases/2020/p0625-update-expands-covid-19.html
WHO. Coronavirus disease (COVID-19). Situation Report – 157. 2020. [cited 2021 Jun 28]. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200625-covid-19-sitrep-157.pdf
Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract [Internet]. 2019 [cited 2022 Jun 28]; 157:107843. Available from: https://doi.org/10.1016/j.diabres.2019.107843
Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med [Internet]. 2020 [cited 2022 Jan 28]; 8(5):475-481. Available from: https://doi.org/10.1016/S2213-2600(20)30079-5
Chen R, Liang W, Jiang M, Guan W, Zhan C, Wang T, Tang C, et al. Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China. Chest[Internet]. 2020 [cited 2022 Jan 28]; 158(1):97-105. Available from: https://doi.org/10.1016/j.chest.2020.04.010
Abdi A, Jalilian M, Sarbarzeh PA, Vlaisavljevic Z. Diabetes and COVID-19: A systematic review on the current evidences. Diabetes Res Clin Pract [Internet]. 2020 [cited 2022 Jan 28];166:108347. Available from: https://doi.org/10.1016/j.diabres.2020.108347
Gregg EW, Sophiea MK, Weldegiorgis M. Diabetes and COVID-19: Population Impact 18 Months Into the Pandemic. Diabetes Care [Internet]. 2021 [cited 2022 Jan 28]; 44(9):1916-1923. Available from: https://doi.org/10.2337/dci21-0001
Wu ZH, Tang Y, Cheng Q. Diabetes increases the mortality of patients with COVID-19: a meta-analysis. Acta Diabetol [Internet]. 2021 [cited 2022 Jan 28]; 58(2):139-144. Available from: https://doi.org/10.1007/s00592-020-01546-0
Akinosoglou K, Schinas G, Bletsa E, Bristianou M, Lanaras L, Michailides C, Katsikas T, Barkas F, Liberopoulos E, Kotsis V, et al. COVID-19 Outcomes and Diabetes Mellitus: A Comprehensive Multicenter Prospective Cohort Study. Microorganisms [Internet]. 2023 [cited 2022 Jan 28]; 11(6):1416. Available from: https://doi.org/10.3390/microorganisms11061416
Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the reports of observational studies in epidemiology (STROBE): explanation and elaboration. PloS Medicine [Internet]. 2007 [cited 2022 Jan 28]; 4(10):1628. Available from: https://doi.org/10.1016/j.ijsu.2014.07.014
Brasil. Ministério da Saúde (BR). Boletins epidemiológicos. Brasília: Secretaria de Vigilância em Saúde; 2020 [cited 2023 Jun 28]. Available from: https://www.gov.br/saude/pt-br/centrais-de-conteudo/publicacoes/boletins/epidemiologicos/edicoes/2022
Clannad E, editor. Diretrizes Sociedade Brasileira de Diabetes 2019 - 2020. São Paulo: Sociedade Brasileira de Diabetes. 2020. 455p. Available from: https://www.saude.ba.gov.br/wp-content/uploads/2020/02/Diretrizes-Sociedade-Brasileira-de-Diabetes-2019-2020.pdf
Ministério da Saúde (BR). Secretaria de Ciência, Tecnologia, Inovação e Insumos Estratégicos em Saúde – SCTIIE. Diretrizes Brasileiras para Tratamento Hospitalar do Paciente com COVID-19 – Capítulo 2: Tratamento Farmacológico. Brasília- DF: 2021 [cited 2023 Jun 28]. Available from: https://www.gov.br/conitec/pt-br/midias/consultas/relatorios/2021/20210517_relatorio_diretrizes_brasileira_covid_capitulo_1_cp_36.pdf
Falavigna M, Colpani V, Stein C, Azevedo LC, Bagattini AM, Brito GV, et al. Diretrizes para o tratamento farmacológico da COVID-19. Rev Bras Ter Intensiva[Internet]. 2020[cited 2023 Jan 28]; 32:166-96. Available from: https://doi.org/10.5935/0103-507X.20200039
Falavigna M, Belli KC, Barbosa AN, Zavascki AP, Nastri ACDSS, Santana CM et al. Diretrizes Brasileiras para o tratamento farmacológico de pacientes hospitalizados com COVID-19: Diretriz conjunta da Associação Brasileira de Medicina de Emergência, Associação de Medicina Intensiva Brasileira, Associação Médica Brasileira, Sociedade Brasileira de Angiologia e Cirurgia Vascular, Sociedade Brasileira de Infectologia, Sociedade Brasileira de Pneumologia e Tisiologia e Sociedade Brasileira de Reumatologia. Revista Brasileira de Terapia Intensiva [Internet]. 2022[cited 2023 Jan 28]; 26(2):102347. Available from: https://doi.org/10.5935/0103-507X.20220001-pt
Gomes C. Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19). Braz J Implantol Health Sci [Internet].2020 [cited 2023 Jan 28]; 2(3) Available from: https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf
Huang J, Xiao Y, Zheng P, Zhou W, Wang Y, Huang G, Xu A, Zhou Z. Distinct neutrophil counts and functions in newly diagnosed type 1 diabetes, latent autoimmune diabetes in adults, and type 2 diabetes. Diabetes Metab Res Rev[Internet]. 2019 [cited 2023 Jan 28];35(1):e3064. Available from: https://doi.org/10.1002/dmrr.3064
Erener S. Diabetes, infection risk and COVID-19. Mol Metab[Internet]. 2020 [cited 2023 Jan 28]; 39:101044. Available from: https://doi.org/10.1016/j.molmet.2020.101044
Patel AJ, Klek SP, Peragallo-Dittko V, Goldstein M, Burdge E, Nadile V, et al. Correlation of Hemoglobin A1C and Outcomes in Patients Hospitalized With COVID-19. Endocr Pract[Internet]. 2021 [cited 2023 Jan 28];27(10):1046-1051. Available from: https://doi.org/10.1016/j.eprac.2021.07.008
Chen J, Wu C, Wang X, Yu J, Sun Z. The Impact of COVID-19 on Blood Glucose: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne) [Internet]. 2020 [cited 2023 Jan 28]; 11:574541. Available from: https://doi.org/10.3389/fendo.2020.574541
Almeida C, Ferreira A, Duarte D, Viegas AF, Santos A, Vaz A, Nascimento E. Glycemic Control in Type 1 Diabetes Mellitus and COVID-19: What We Learned From the Lockdown Experience. Cureus[Internet]. 2023[cited 2023 Jan 28]; 15(1):e33340. Available from: https://doi.org/10.7759/cureus.33340
Numaguchi R, Kurajoh M, Hiura Y, Imai T, Morioka T, Saito M, et al. Glycated hemoglobin level on admission associated with progression to severe disease in hospitalized patients with non-severe coronavirus disease 2019. J Diabetes Investig[Internet]. 2022 [cited 2023 Jan 28];13(10):1779-1787. Available from: https://doi.org/10.1111/jdi.13845
